MedTrace Logo

HERVIN: Trastuzumab and Vinorelbine in Metastatic Breast Cancer

NCT00401427 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2012-07-13

No results posted yet for this study

Summary

The combination of vinorelbine with weekly trastuzumab has produced high response rate in HER2 overexpressing metastatic breast cancer (MBC). The present phase 2 study was planned to test activity of the same combination, with trastuzumab given every 3 weeks, rather than weekly.

Conditions

Interventions

DRUG

trastuzumab

DRUG

vinorelbine

Sponsors & Collaborators

  • National Cancer Institute, Naples

    lead OTHER

Principal Investigators

  • Andrea De Matteis, M.D. · NCI Naples, Division of Medical Oncology C

  • Francesco Perrone, M.D., Ph.D. · NCI Naples, Clinical Trials Unit

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-11-30
Primary Completion
2006-06-30
Completion
2006-12-31

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00401427 on ClinicalTrials.gov